Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share

Orexigen Therapeutics (NASDAQ: OREX) reported Q2 EPS of ($2.00), versus ($1.73) reported last year. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $19.14 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight